Myriad presents Prolaris data at AUA, 7/14

July 2014—Myriad Genetics presented new data from a clinical validation study of Prolaris at the American Urological Association annual meeting in May. A key finding was that the Prolaris molecular diagnostic test accurately differentiated newly diagnosed patients who were likely to die from prostate cancer within 10 years from those with lower-risk disease. The goal was to validate the Prolaris test score in 761 conservatively managed prostate cancer patients diagnosed by needle biopsy. The primary endpoint was prostate cancer death, and the median follow up was 9.5 years. The results showed that for each one unit increase in the Prolaris score, patients had approximately double the risk of dying from prostate cancer.

In the second study featured at AUA, 230 men who had pathologic Gleason scores of either 3 + 4 or 4 + 3 were examined. The Prolaris test was performed on the samples, and the rates of biochemical recurrence (BCR) were compared in each group. The results showed there was no difference in BCR based on an assessment using Gleason score alone. However, the Prolaris test significantly outperformed the current practice of upgrading to Gleason 3 + 4 or 4 + 3 in predicting which patients would experience biochemical recurrence after a radical prostatectomy.

The third study presented at AUA evaluated the prognostic utility of the Prolaris score generated from needle biopsy in men treated with prostatectomy. This study found that the Prolaris test was the strongest predictor of metastatic disease compared with other tested clinical variables. Patients with a high Prolaris score have more than a sixfold higher risk of developing metastases compared to patients with a low score.

Myriad Genetics, 801-584-3065